Docetaxel plus radiotherapy for head and neck cancer

被引：1
作者：
De Felice, Francesca [1 ,2 ]
机构：
[1] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Policlin Umberto 1, Radiat Oncol, Viale Regina Elena 326, I-00161 Rome, Italy
[2] Sapienza Univ Rome, Dept Radiotherapy, Policlin Umberto 1, Viale Regina Elena 326, Rome, Italy
来源：
ORAL ONCOLOGY | 2023年 / 139卷
关键词：
Chemoradiotherapy; Cisplatin; Docetaxel; Radiotherapy; Head neck cancer; Toxicity;
D O I：
10.1016/j.oraloncology.2023.106359
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Selenium substitution during radiotherapy in head and neck cancer
    Buentzel, J.
    Micke, O.
    Glatzel, M.
    Schaefer, U.
    Riesenbeck, D.
    Kisters, K.
    Bruns, F.
    Schoenekaes, K. G.
    Dawczynski, H.
    Muecke, R.
    TRACE ELEMENTS AND ELECTROLYTES, 2010, 27 (04) : 235 - 239
  • [22] Advances in radiotherapy for head and neck cancer
    Iorio, Giuseppe Carlo
    Denaro, Nerina
    Livi, Lorenzo
    Desideri, Isacco
    Nardone, Valerio
    Ricardi, Umberto
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] Influence of hypoxia on the radiotherapy response in HPV plus and HPV- head and neck cancer
    Wegge, Marilyn
    Dok, Ruveyda
    Dubois, Ludwig J.
    Nuyts, Sandra
    RADIOTHERAPY AND ONCOLOGY, 2024, 192 : S53 - S54
  • [24] Cytogenetic damage of radiotherapy in long-term head and neck cancer survivors
    Unal, Dilek
    Kiraz, Aslihan
    Avci, Deniz
    Tasdemir, Arzu
    Unal, Tuba Dilay
    Cagli, Sedat
    Eroglu, Celalettin
    Yuce, Imdat
    Ozcan, Ibrahim
    Kaplan, Bunyamin
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2016, 92 (07) : 364 - 370
  • [25] Toxicity of Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil for Advanced Head and Neck Cancer
    Billan, Salem
    Kaidar-Person, Orit
    Atrash, Fadi
    Doweck, Ilana
    Haim, Nissim
    Kuten, Abraham
    Ronen, Ohad
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2013, 15 (05): : 231 - 235
  • [26] Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy
    Mencoboni, M.
    Grillo-Ruggieri, F.
    Salami, A.
    Scasso, F.
    Rebella, L.
    Grimaldi, A.
    Dellepiane, M.
    Moratti, G.
    Bruzzone, A.
    Spigno, F.
    Ghio, R.
    Figliomeni, M.
    EUROPEAN JOURNAL OF CANCER CARE, 2011, 20 (04) : 503 - 507
  • [27] Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer
    Nakamura, Tatsuya
    Fuwa, Nobukazu
    Takayama, Kanako
    Inokuchi, Haruo
    Tomoda, Takuya
    Takada, Akinori
    Makita, Chiyoko
    Shiomi, Miho
    Yokouchi, Jun-ichi
    Watanabe, Kazuo
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2012, 34 (11): : 1634 - 1639
  • [28] Docetaxel and Irinotecan in Recurrent or Metastatic Head and Neck Cancer
    Argiris, Athanassios
    Buchanan, Ashley
    Brockstein, Bruce
    Kolesar, Jill
    Ghebremichael, Musie
    Pins, Michael
    Hahn, Kristine
    Axelrod, Rita
    Forastiere, Arlene
    CANCER, 2009, 115 (19) : 4504 - 4513
  • [29] Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)
    Agustí Barnadas
    Ricard Mesía
    Margarita Majem
    Ramón Galiana
    Antonio López-Pousa
    José M. de Vega
    Mireia Margelí
    Vicente Valentí
    Lluís Anglada
    Ariadna Lloansí
    Antonio Arellano
    Clinical and Translational Oncology, 2011, 13 : 254 - 260
  • [30] Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial
    Imamura, Yoshinori
    Tanaka, Kaoru
    Kiyota, Naomi
    Hayashi, Hidetoshi
    Ota, Ichiro
    Arai, Akihito
    Iwae, Shigemichi
    Minami, Shujiro
    Yane, Katsunari
    Yamazaki, Tomoko
    Nagatani, Yoshiaki
    Toyoda, Masanori
    Takahama, Takayuki
    Sakai, Kazuko
    Nishio, Kazuto
    Otsuki, Naoki
    Nibu, Ken-ichi
    Minami, Hironobu
    MEDICAL ONCOLOGY, 2021, 38 (11)
12345